Beta Bionics hit net sales of $44.7m in the first nine months of 2024, marking an increase from $3.6m in 2023. Beta Bionics’ ...

Beta Bionics has announced the pricing of its upsized initial public offering of 12 million shares of common stock at a price to the public of $17 per share.

Abbott Laboratories’ ABT growth in the fourth quarter of 2024 can be attributed to strong improvement in global Core ...

With a solid foundation for growth and a promising outlook, the global lancet market is on track to achieve its projected USD ...

Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose ...

Global healthcare leader Abbott has developed Ensure Gold, a science-based nutrition solution available in both powder and ...

A few weeks ago, an allergist prescribed a two-week course of an oral steroid to clear up my sinus inflammation. Before I ...

Abbott (NYSE:ABT) today highlighted significant growth within its Diabetes business amid its fourth-quarter results for 2024.

For the full calendar of 2024, Abbott recorded sales of $41.95 billion, following the launches last year of a new heart valve ...

Abbott Laboratories ABT is set to report fourth-quarter fiscal 2024 results on Jan. 22. See the Zacks Earnings Calendar to ...

DexCom's stock is fairly valued despite positive Q4 2024 results, with muted enthusiasm from Wall Street today. Click here to find out why I am neutral on DXCM.

Sayer previewed other upcoming features for Dexcom’s CGMs, including plans to launch a 15-day sensor in the second half of the year. Competitor Abbott currently has 15-day sensors with its Freestyle ...